BioInvent International AB has carried out a directed issue of approximately SEK 85 million

BioInvent International has carried out a directed issue raising approximately SEK 85 million through an accelerated book building process.

BioInvent International AB is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The company has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. BioInvent International’s shares are listed on Nasdaq Stockholm.

BioInvent International was advised by Mannheimer Swartling in the transaction.


This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.